Skip to content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc.

RFL

Rafael Holdings is a biotechnology company focused on developing pharmaceuticals and medical devices for rare diseases and oncology.

Market cap
$118.04M+56.4%
Revenue$980.0K+33.9%
Net income-$20.7M+9.4%
Free cash flow-$23.2M-182%
EPS (diluted)-$0.71+24.5%
Trailing twelve months · change vs. prior year

Earnings

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
Free cash flow-$7.3M-128%

Valuation & ratios

Valuation

See full
Market cap$118.04M+56.4%
P/S120.5×+26.9×

Profitability

See full
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Current ratio3.2×-0.7×

Segments

By product

See full
Product Revenue$89.0K-63.4%
Rental Third Party$60.0K+22.4%
Rental Related Party$30.0K+7.1%

Competitors

Profile

Rafael Holdings is a biotechnology company focused on developing pharmaceuticals and medical devices for rare diseases and oncology. The company's primary value proposition is the clinical advancement of its lead drug candidate, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1. Additionally, the firm manages a diverse portfolio of majority-owned subsidiaries specializing in cancer metabolism, orthopedic surgical instruments, and bioavailability technologies.

Competitive position

A clinical-stage developer focused on orphan drug designations and niche orthopedic markets, transitioning from a real estate holding company to a pure-play biotech entity.

GeographiesUnited States, Israel, European Union
Customer segmentsHealthcare Providers, Pharmaceutical Manufacturers, Commercial Tenants
Business modelR&D-stage biotechnology, IP Licensing, Asset Management
SuppliersContract Manufacturing Organizations (CMOs), Academic research institutions, Clinical research organizations (CROs), Raw material suppliers for cyclodextrins
CustomersSpecialty pharmacies, Hospitals, Medical device distributors, Third-party pharmaceutical manufacturers
Listed2018
Employees13.0
CEOHoward S. Jonas
FilingsSEC EDGAR

Questions, answered.

What is Rafael Holdings, Inc.'s market cap?
Rafael Holdings, Inc. (RFL) has a market capitalization of $118.0M and trades on NYSE.
What is Rafael Holdings, Inc.'s revenue and profitability?
Rafael Holdings, Inc. generated $980.0K in trailing twelve-month revenue with a net loss of $20.7M, representing a net margin of -2117.2%. Gross margin stands at 71.9%, with free cash flow of -$23.2M. These figures are based on the Q2 2026 filing.
Who are Rafael Holdings, Inc.'s competitors?
Rafael Holdings, Inc.'s key competitors include Johnson & Johnson, Zevra Therapeutics, Intel, and others. These companies compete in similar markets and product categories.
Who does Rafael Holdings, Inc. partner with?
Rafael Holdings, Inc.'s notable partners include Princeton University, Ludwig Institute for Cancer Research, Yissum Research and Development Company, and others.
What subsidiaries does Rafael Holdings, Inc. have?
Rafael Holdings, Inc.'s subsidiaries include Cyclo Therapeutics, LLC, LipoMedix Pharmaceuticals Ltd., Cornerstone Pharmaceuticals, Inc., and others.
Where is Rafael Holdings, Inc. headquartered?
Rafael Holdings, Inc. is headquartered in United States of America and employs approximately 13 people. It has been publicly traded since 2018.